The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Chemoradiation-related lymphopenia and its association with survival in patients with anal cancer.
 
Grace Lee
No Relationships to Disclose
 
Daniel W. Kim
No Relationships to Disclose
 
Vinayak Muralidhar
No Relationships to Disclose
 
Devarati Mitra
No Relationships to Disclose
 
Nora Horick
No Relationships to Disclose
 
Christine Elissa Eyler
No Relationships to Disclose
 
Theodore S. Hong
Consulting or Advisory Role - Clinical Genomics; Clinical Genomics; Clinical Genomics; Clinical Genomics; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Merck; Merck; Merck; Merck
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Intrinsic LifeSciences (Inst); Intrinsic LifeSciences (Inst); Intrinsic LifeSciences (Inst); Intrinsic LifeSciences (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst)
 
Lorraine C. Drapek
No Relationships to Disclose
 
Jill N. Allen
No Relationships to Disclose
 
Lawrence Scott Blaszkowsky
Stock and Other Ownership Interests - Pfizer (I); Pfizer (I); Pfizer (I); Pfizer (I)
 
Bruce J. Giantonio
No Relationships to Disclose
 
Aparna Raj Parikh
Consulting or Advisory Role - Driver, Inc; Driver, Inc; Driver, Inc; Driver, Inc; Eisai; Eisai; Eisai; Eisai; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; PureTech; PureTech; PureTech; PureTech
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Eisai; Eisai; Eisai; Eisai
 
David P. Ryan
Stock and Other Ownership Interests - Acworth Pharmaceuticals; Acworth Pharmaceuticals; Acworth Pharmaceuticals; Acworth Pharmaceuticals; MPM Capital; MPM Capital; MPM Capital; MPM Capital
Honoraria - Research to Practice; Research to Practice; Research to Practice; Research to Practice; UpToDate; UpToDate; UpToDate; UpToDate
Consulting or Advisory Role - Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; Maverick Therapeutics; Maverick Therapeutics; Maverick Therapeutics; Maverick Therapeutics; MPM Capital; MPM Capital; MPM Capital; MPM Capital; Oncorus; Oncorus; Oncorus; Oncorus; TCR2 Therapeutics; TCR2 Therapeutics; TCR2 Therapeutics; TCR2 Therapeutics; Twentyeight-Seven Therapeutics; Twentyeight-Seven Therapeutics; Twentyeight-Seven Therapeutics; Twentyeight-Seven Therapeutics
Research Funding - Stand up to Cancer (Inst); Stand up to Cancer (Inst); Stand up to Cancer (Inst); Stand up to Cancer (Inst)
Patents, Royalties, Other Intellectual Property - Johns Hopkins University Press; Johns Hopkins University Press; Johns Hopkins University Press; Johns Hopkins University Press; McGraw Hill Chapter Royalties; McGraw Hill Chapter Royalties; McGraw Hill Chapter Royalties; McGraw Hill Chapter Royalties
Other Relationship - TCR2 Therapeutics; TCR2 Therapeutics; TCR2 Therapeutics; TCR2 Therapeutics
 
Jeffrey William Clark
Consulting or Advisory Role - Emas pharma; Emas pharma; Emas pharma; Emas pharma
Research Funding - Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
 
Jennifer Yon-Li Wo
No Relationships to Disclose